Jiangsu Hengrui Pharmaceuticals Q1 Growth

Jiangsu Hengrui reported robust financial results for Q1 2026, with revenue increasing by 12.98% year-over-year to RMB 8.14 billion and net profit attributable to shareholders rising by 21.78% to RMB 2.28 billion. Innovative drugs were a primary growth driver, contributing RMB 4.53 billion in revenue. The company continued its innovation-driven strategy with RMB 2.22 billion in R&D investments. Key achievements include the approval of three innovative products and new indications in China, 26 clinical trial approvals, and 8 new drug applications accepted in China. Business development also contributed significantly, with RMB 787 million in out-licensing revenue, largely from a collaboration with GSK plc. A major milestone was the successful Nasdaq-100 listing of Kailera Therapeutics, a NewCo company formed around Jiangsu Hengrui' GLP-1 assets, which reflects progress in its NewCo strategy and global GLP-1 portfolio development.